Case Study

Case study: Mitochondrial toxicity in drug discovery and development

The Agilent Seahorse XF assay platform has opened new avenues for examining mitochondrial health in a timely and effective manner.

Building on the principle of the MST assay, Agilent has developed a streamlined Seahorse XF Mito Tox assay solution that can easily be integrated into a drug discovery workflow with improved throughput and data interpretability. In light of its combination of sensitivity, specificity, and throughput, the XF Mito Tox assay is an ideal approach for confident identification of mitochondrial liability, thus helping to de-risk the drug discovery pipeline.